Drug Trial Radar · NCT05005234
A Study of GFH925 in Patients With Advanced Solid Tumors With KRAS G12C Mutations
Last checked: Nov 19, 2026Latest source record: Nov 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
334
Actual
Start
Sep 13, 2021
Primary completion
Feb 20, 2023
Study completion Dec 20, 2024
Sponsor
- Lead sponsor
- Innovent Biologics (Suzhou) Co. Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 13, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase Ia: To evaluate the safety/tolerability of GFH925 in subjects with KRAS G12C-mutated advanced solid tumors; To estimate the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of GFH925. Phase Ib: To evaluate the efficacy of GFH925 in subjects with KRAS G12C mutant advanced colorectal cancer or other tumors. Phase II: To evaluate the efficacy of GFH925 in subjects with KRAS G12C mutant advanced non-small cell lung cancer (NSCLC).
Conditions
- KRAS G12C
Interventions
GFH925Drug
Administered as an oral tablet formulation
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase Ia: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs); changes in laboratory tests, vital signs, physical examinations, electrocardiograms (ECGs)Time frame: Baseline to 24 Months
- Phase Ia: Incidence of dose-limiting toxicity (DLT) eventsTime frame: At the end of Cycle 1(each cycle is 21 days)
- Phase Ib: ORR per RECIST 1.1Time frame: Continuous evaluation during treatment
- Phase II: ORR assessed by Independent Radiographic Review Committee (IRRC) according to RECIST 1.1Time frame: Continuous evaluation during treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.